- Home
-
About BRC
-
Research
- Research
-
Institute of Biophysics
-
Institute of Biochemistry
-
Institute of Genetics
-
Institute of Plant Biology
- Laboratory of Plant Chrono- and Photobiology
- Laboratory of Molecular Stress- and Photobiology
- Laboratory of Photosynthetic Membranes
- Laboratory of Plant Lipid Function and Structure
- Laboratory of Plant Cell Division Cycle and Stress Adaptation
- Laboratory of Molecular Regulators of Plant Growth
- Laboratory of Functional Cell Biology
- Laboratory of Arabidopsis Molecular Genetics
-
Core Facilities
-
Services
- Lectures/Seminars
-
Education
- Innovation
-
Conferences
- News
- Open positions
- Phonebook
-
Public Information
Csaba VIZLER
principal investigator
| Katalin JÓSVAY | junior research associate |
| Annamária MARTON | Ph.D. student |
| Erzsébet KUSZ | technician |
LABORATORY OF MOLECULAR PHARMACOLOGY
Beside his participation in the projects of the Laboratory of Cytokine Research, Csaba Vizler directs a pharmacological research sub-group that uses animal disease models and cell culture for mechanism of action studies and pre-clinical testing of drug candidates developed either in house or by Hungarian biotech companies. Three main research lines are pursued. (1) Studies on the anti-tumoral effect, pharmacokinetics and mode of action of novel anti-cancer drugs; (2) Development and testing of immunomodulating peptides and small molecules; (3) The TRPV1 pain receptor (capsaicin receptor) is the major receptor involved in the generation of inflammatory pain and neuropathic pain. The research sub-group studies the pharmacology and physiology of the TRPV1 receptor and develops receptor antagonists and channel blockers for the treatment of cancer pain and neuropathies.
The portfolio of the group consists of numerous in vivo mouse disease models (transplantable tumors, graft-versus-host disease, DTH, streptozocin diabetes, analgesia assays, experimental allergic encephalomyelitis), mammalian tissue culture, in vitro immunoassays, medium-throughput isotope influx- and luminescent reporter cell assays and hybridoma technology.
Selected publications
Delarasse, C., Daubas, P., Mars, L.T., Vizler, C., Litzenburger, T., Iglesias, A., Bauer, J., Della Gaspera, B., Schubart, A., Decker, L., Dimitri, D., Roussel, G., Dierich, A., Amor, S., Dautigny, A., Liblau, R. and Pham-Dinh, D. (2003). Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J Clin. Invest. 112: 544-553.
Fantin, M., Quintieri, L., Kusz, E., Kis, E., Glavinas, H., Floreani, M., Padrini, M., Duda, E. and Vizler, C. (2006). Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties. Eur. J. Pharmacol. 535: 301-309.
Quintieri, L., Fantin, M. and Vizler, C. (2007). Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. Adv. Exp. Med. Biol. 593: 595-104.
Pecze, L., Szabó, K., Széll, M., Jósvay, K., Kaszás, K., Kusz, E., Letoha, T., Prorok, J., Koncz, I., Tóth, A., Kemény, L., Vizler, C. and Oláh, Z. (2008). Human keratinocytes are vanilloid resistant. PLoS ONE.3(10): e3419.
Pecze, L., Pelsőczi, P., Kecskés, M., Winter, Z., Papp, A., Kaszás, K., Letoha, T., Vizler, C. and Oláh, Z. (2009). Resiniferatoxin mediated ablation of TRPV1+ neurons removes TRPA1 as well. Can. J. Neurol. Sci. 36: 234-241.
Szabó, A., Varga, R., Keresztes, M., Vizler, C., Németh, I., Rázga, Z. and Boros, M. (2009). Ischemic limb preconditioning downregulates systemic inflammatory activation. J. Orthop. Res. 27(7):897-902.